Spotlight Innovation Inc. (STLT) 1.2500 $STLT
Spotlight Innovation Subsidiary Celtic Biotech Product EPISORB Available to Compounding Pharmacy Industry
Marketwired - Mon Apr 06, 12:44PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that the product EPISORB, developed by its subsidiary Celtic Biotech Iowa, Inc., has been registered with the U.S. Food and Drug Administration and has been incorporated into the Pharmacy Benefit Managers (PBM) database referenced by health insurance companies when reimbursing drugs. The product makes use of the attributes of cardiotoxin as a cell penetrating peptide and is intended for distribution through the compounding pharmacy industry.
Spotlight Innovation Enters Into Purchase Agreement With Memcine Pharmaceuticals
Marketwired - Tue Mar 17, 12:50PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that Spotlight Innovation Inc. entered into a Purchase Agreement with Coralville, Iowa-based Memcine Pharmaceuticals, Inc. Pursuant to the agreement, Spotlight Innovation will acquire a majority of the outstanding securities of Memcine Pharmaceuticals. The closing of the transaction is contingent upon several conditions including, but not limited to, completion of due diligence and entry into a shareholder agreement.
Spotlight Innovation Subsidiary Celtic Biotech Iowa Licenses Promising Therapy for Chronic Kidney Disease
Marketwired - Tue Mar 10, 2:46PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa, Inc., entered into an exclusive, world-wide (excluding China) license agreement to develop and market a patent-pending invention related to the treatment of acute and chronic nephropathy, Use of Cardiotoxin for the Treatment of Chronic Kidney Disease (CKD). Animal studies have shown that cardiotoxin has the ability to inhibit the inflammatory immune processes that damage the kidneys, can reduce the level of proteinurea, serum creatinine and urea in chronic neuropathy, and recover renal function and reduce renal injury.
Spotlight Innovation Subsidiary Celtic Biotech Iowa Granted Patent by the U.S. Patent and Trademark Office
Marketwired - Thu Jan 15, 1:22PM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa Inc. has been granted U.S. Patent entitled Crotoxin Administration for Cancer Treatment and Pain Relief. The invention relates to Crotoxin compositions for intravenous administration and methods of use of Crotoxin for the treatment of pain and/or for the treatment of neurologic and neuromuscular disorders.
Spotlight Innovation Signs Memorandum of Understanding (MOU) With Black Swan LLC
Marketwired - Tue Jan 06, 10:01AM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces that it has entered into a Memorandum of Understanding with Black Swan LLC. Under the agreement, Black Swan will assist with activities such as identifying applicable government grants and loans, affecting beneficial changes to the legislative environment, advancing emerging technologies, identifying business partners, and developing new markets, particularly in the government sector.
Spotlight Innovation Announces Change of Transfer Agent
Marketwired - Tue Dec 16, 8:03AM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces today that effective December 16, 2014, Spotlight Innovation is replacing Securities Transfer Corporation as the transfer agent and registrar of the securities of the Company.
Celtic Biotech Iowa Requests Reactivation and Transfer of National Drug Code Registration
Marketwired - Thu Dec 04, 9:30AM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces that a request was submitted to the Center for Drug Evaluation and Research at the Food and Drug Administration to reactivate and transfer the Celtic Biotech (Ireland) National Drug Code (NDC) registration to Celtic Biotech Iowa Inc. in anticipation of the manufacture and commercialization of a proprietary transdermal delivery gel product. The novel gel formula, originally developed by scientists at Celtic Biotech to facilitate the topical delivery of its proprietary biologic analgesic and anti-inflammatory drugs, is designed to provide a convenient platform for the compounding pharmacy industry to prepare and effectively deliver topical pain medications.
Spotlight Innovation Signs Letter of Intent to Acquire Memcine Pharmaceuticals
Marketwired - Tue Oct 14, 3:51PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announced that it has signed a Letter of Intent to acquire majority ownership in Memcine Pharmaceuticals Inc., located at the University of Iowa Research Park in Coralville, Iowa. Memcine Pharmaceuticals is developing its Immunoplex(TM) vaccine platform technology, which is designed to use the body's own naturally occurring targeting system to deliver vaccine components to immune cells and stimulate a robust response.
Spotlight Innovation Retains Jerry Cirino as Special Advisor
ACCESSWIRE - Wed Oct 01, 1:21PM CDT
Image: http://www.accesswire.com/images/1075/STLT%20...o%20AW.jpg
Spotlight Innovation Retains Barwicki Investor Relations to Provide Global Investor Relations Program
ACCESSWIRE - Wed Sep 24, 1:04PM CDT
Image: http://www.accesswire.com/images/1075/STLT%20...o%20AW.jpg
New White Paper From Spotlight Innovation Focuses on Evolution of Efforts to Transform University Research into Profitable Business Ventures
eTeligis - Wed Aug 27, 10:40AM CDT
WEST DES MOINES, IA, United States, via ETELIGIS INC., 08/27/2014 - - Spotlight Innovation, Inc. (OTCQB: STLT) today published a white paper reporting the progress and growth of the transfer and commercialization of university-generated research and intellectual property (IP). Midwest Universities are Cultivating IP Commercialization Success explores how the changing policies of the federal government in conjunction with innovations from the academic and business communities are creating new opportunities for Universities, researchers and other stakeholders to turn transformative ideas into profitable business ventures.
Spotlight Innovation Signs Second Letter of Credit with Denver Savings Bank
ACCESSWIRE - Tue Aug 05, 12:35PM CDT
WEST DES MOINES, IA / ACCESSWIRE / August 5, 2014 / Spotlight Innovation, Inc. (OTCQB:STLT) has entered into a second Letter of Credit with Denver Savings Bank, located in Denver, Iowa, in the amount of $250,000.00, effective July 29, 2014.
Spotlight Innovation, Inc. Announces Closing of Financing
eTeligis - Wed Jul 02, 3:21PM CDT
WEST DES MOINES, IOWA, United States, via eTeligis Inc., 07/02/2014 - - Spotlight Innovation, Inc. (OTCQB:STLT) is pleased to announce that it has closed an equity placement of more than $41,418,000 with nine accredited investors through its equity advisor Catwalk Capital, LLC. Pursuant to the terms of the financing the funds have been deposited in a restricted account with an intermediary whereby the funds are released to the Company according to business, market development and valuation milestones.
Spotlight Innovation Names Dr. David Hostelley Chief Financial Officer
Marketwire - Thu Jun 26, 3:45PM CDT
Spotlight Innovation, Inc. (OTCQB: STLT) today announced that effective June 20, 2014, Dr. David Hostelley has been named Chief Financial Officer of the Company. Dr. Hostelley has spent twenty years as a consultant in the health field. He has structured numerous acquisitions in the fields of printing, oil and gas development, private schools, insurance agencies, hotels, manufacturing, debit card issuance, health products and health clubs, and service entities. He has formed Not-For-Profit entities and serves on the board of trustees. Dr. Hostelley is a CPA (inactive) licensed by the state of Ohio. He earned his Ph.D. in management while a lecturer in the MBA Program of Baldwin-Wallace College, and has lectured in Accounting and Management for Walsh University, North Canton, Ohio. During his more than twenty years in business he has served as CEO, CFO and board member of several publicly traded companies.
Spotlight Innovation Subsidiary Celtic Biotech Product EPISORB Available to Compounding Pharmacy Industry
Marketwired - Mon Apr 06, 12:44PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that the product EPISORB, developed by its subsidiary Celtic Biotech Iowa, Inc., has been registered with the U.S. Food and Drug Administration and has been incorporated into the Pharmacy Benefit Managers (PBM) database referenced by health insurance companies when reimbursing drugs. The product makes use of the attributes of cardiotoxin as a cell penetrating peptide and is intended for distribution through the compounding pharmacy industry.
Spotlight Innovation Enters Into Purchase Agreement With Memcine Pharmaceuticals
Marketwired - Tue Mar 17, 12:50PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that Spotlight Innovation Inc. entered into a Purchase Agreement with Coralville, Iowa-based Memcine Pharmaceuticals, Inc. Pursuant to the agreement, Spotlight Innovation will acquire a majority of the outstanding securities of Memcine Pharmaceuticals. The closing of the transaction is contingent upon several conditions including, but not limited to, completion of due diligence and entry into a shareholder agreement.
Spotlight Innovation Subsidiary Celtic Biotech Iowa Licenses Promising Therapy for Chronic Kidney Disease
Marketwired - Tue Mar 10, 2:46PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa, Inc., entered into an exclusive, world-wide (excluding China) license agreement to develop and market a patent-pending invention related to the treatment of acute and chronic nephropathy, Use of Cardiotoxin for the Treatment of Chronic Kidney Disease (CKD). Animal studies have shown that cardiotoxin has the ability to inhibit the inflammatory immune processes that damage the kidneys, can reduce the level of proteinurea, serum creatinine and urea in chronic neuropathy, and recover renal function and reduce renal injury.
Spotlight Innovation Subsidiary Celtic Biotech Iowa Granted Patent by the U.S. Patent and Trademark Office
Marketwired - Thu Jan 15, 1:22PM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa Inc. has been granted U.S. Patent entitled Crotoxin Administration for Cancer Treatment and Pain Relief. The invention relates to Crotoxin compositions for intravenous administration and methods of use of Crotoxin for the treatment of pain and/or for the treatment of neurologic and neuromuscular disorders.
Spotlight Innovation Signs Memorandum of Understanding (MOU) With Black Swan LLC
Marketwired - Tue Jan 06, 10:01AM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces that it has entered into a Memorandum of Understanding with Black Swan LLC. Under the agreement, Black Swan will assist with activities such as identifying applicable government grants and loans, affecting beneficial changes to the legislative environment, advancing emerging technologies, identifying business partners, and developing new markets, particularly in the government sector.
Spotlight Innovation Announces Change of Transfer Agent
Marketwired - Tue Dec 16, 8:03AM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces today that effective December 16, 2014, Spotlight Innovation is replacing Securities Transfer Corporation as the transfer agent and registrar of the securities of the Company.
Celtic Biotech Iowa Requests Reactivation and Transfer of National Drug Code Registration
Marketwired - Thu Dec 04, 9:30AM CST
Spotlight Innovation Inc. (OTCQB: STLT) announces that a request was submitted to the Center for Drug Evaluation and Research at the Food and Drug Administration to reactivate and transfer the Celtic Biotech (Ireland) National Drug Code (NDC) registration to Celtic Biotech Iowa Inc. in anticipation of the manufacture and commercialization of a proprietary transdermal delivery gel product. The novel gel formula, originally developed by scientists at Celtic Biotech to facilitate the topical delivery of its proprietary biologic analgesic and anti-inflammatory drugs, is designed to provide a convenient platform for the compounding pharmacy industry to prepare and effectively deliver topical pain medications.
Spotlight Innovation Signs Letter of Intent to Acquire Memcine Pharmaceuticals
Marketwired - Tue Oct 14, 3:51PM CDT
Spotlight Innovation Inc. (OTCQB: STLT) announced that it has signed a Letter of Intent to acquire majority ownership in Memcine Pharmaceuticals Inc., located at the University of Iowa Research Park in Coralville, Iowa. Memcine Pharmaceuticals is developing its Immunoplex(TM) vaccine platform technology, which is designed to use the body's own naturally occurring targeting system to deliver vaccine components to immune cells and stimulate a robust response.
Spotlight Innovation Retains Jerry Cirino as Special Advisor
ACCESSWIRE - Wed Oct 01, 1:21PM CDT
Image: http://www.accesswire.com/images/1075/STLT%20...o%20AW.jpg
Spotlight Innovation Retains Barwicki Investor Relations to Provide Global Investor Relations Program
ACCESSWIRE - Wed Sep 24, 1:04PM CDT
Image: http://www.accesswire.com/images/1075/STLT%20...o%20AW.jpg
New White Paper From Spotlight Innovation Focuses on Evolution of Efforts to Transform University Research into Profitable Business Ventures
eTeligis - Wed Aug 27, 10:40AM CDT
WEST DES MOINES, IA, United States, via ETELIGIS INC., 08/27/2014 - - Spotlight Innovation, Inc. (OTCQB: STLT) today published a white paper reporting the progress and growth of the transfer and commercialization of university-generated research and intellectual property (IP). Midwest Universities are Cultivating IP Commercialization Success explores how the changing policies of the federal government in conjunction with innovations from the academic and business communities are creating new opportunities for Universities, researchers and other stakeholders to turn transformative ideas into profitable business ventures.
Spotlight Innovation Signs Second Letter of Credit with Denver Savings Bank
ACCESSWIRE - Tue Aug 05, 12:35PM CDT
WEST DES MOINES, IA / ACCESSWIRE / August 5, 2014 / Spotlight Innovation, Inc. (OTCQB:STLT) has entered into a second Letter of Credit with Denver Savings Bank, located in Denver, Iowa, in the amount of $250,000.00, effective July 29, 2014.
Spotlight Innovation, Inc. Announces Closing of Financing
eTeligis - Wed Jul 02, 3:21PM CDT
WEST DES MOINES, IOWA, United States, via eTeligis Inc., 07/02/2014 - - Spotlight Innovation, Inc. (OTCQB:STLT) is pleased to announce that it has closed an equity placement of more than $41,418,000 with nine accredited investors through its equity advisor Catwalk Capital, LLC. Pursuant to the terms of the financing the funds have been deposited in a restricted account with an intermediary whereby the funds are released to the Company according to business, market development and valuation milestones.
Spotlight Innovation Names Dr. David Hostelley Chief Financial Officer
Marketwire - Thu Jun 26, 3:45PM CDT
Spotlight Innovation, Inc. (OTCQB: STLT) today announced that effective June 20, 2014, Dr. David Hostelley has been named Chief Financial Officer of the Company. Dr. Hostelley has spent twenty years as a consultant in the health field. He has structured numerous acquisitions in the fields of printing, oil and gas development, private schools, insurance agencies, hotels, manufacturing, debit card issuance, health products and health clubs, and service entities. He has formed Not-For-Profit entities and serves on the board of trustees. Dr. Hostelley is a CPA (inactive) licensed by the state of Ohio. He earned his Ph.D. in management while a lecturer in the MBA Program of Baldwin-Wallace College, and has lectured in Accounting and Management for Walsh University, North Canton, Ohio. During his more than twenty years in business he has served as CEO, CFO and board member of several publicly traded companies.
